News releases

You are here

Major Donation Will Improve, Sustain Sexual Health Research and Care

Monday, March 6, 2017

The University of Minnesota Medical School today announced a significant donation that will provide sustained support for its Program in Human Sexuality while providing an incentive for additional individual donations. This area of health care is facing a shortage of funding for research and care programs across the country.

UMN researchers find reducing radiation therapy exposure leads to lower rate of secondary cancer in survivors

Tuesday, February 28, 2017

Survivors of childhood cancers have fewer secondary cancers, according to new research from the Masonic Cancer Center, University of Minnesota and St. Jude Children’s Research Hospital. Compared with those diagnosed in the 1970s, patients diagnosed after 1990 are experiencing better outcomes. Researchers believe the difference comes from a reduction in exposure to therapeutic radiation.

The results are published today in the Journal of the American Medical Association. Work was led by the Masonic Cancer Center, University of Minnesota in partnership with investigators at St. Jude Children’s Research Hospital. It utilized data from the Childhood Cancer Survivor Study (CCSS).

Cancer drug developed by Masonic Cancer Center, University of Minnesota researchers increases survival in dogs; shows potential for use in humans

Monday, February 13, 2017

A breakthrough trial at the Masonic Cancer Center, University of Minnesota testing a new UMN-developed drug resulted in improved survival rates for dogs diagnosed with a cancer called hemangiosarcoma (HSA). The results were recently published in the journal Molecular Cancer Therapeutics.


Biology of Osteosarcoma (BOOST) Registry and Biobank launches online for families, researchers battling osteosarcoma

Thursday, January 12, 2017

University of Minnesota researchers launch a new website commemorating Zach Sobiech and his legacy. The project brings patients with osteosarcoma together in one online location.  Found at, the site is known as Biology of Osteosarcoma (BOOST) Registry and Biobank. The power of the project comes from the ability to bring people with a rare condition from anywhere in the world together to help better understand this disease.

UMN researchers provide molecular portraits of a new cancer drug target

Monday, December 19, 2016

Unprecedented images of cancer genome-mutating enzymes acting on DNA provide vital clues into how the enzymes work to promote tumor evolution and drive poor disease outcomes. These images, revealed by University of Minnesota researchers, provide the first ever high-resolution pictures of molecular complexes formed between DNA and the human APOBEC3A and APOBEC3B enzymes.

 The research is published online in Nature Structural and Molecular Biology.

Frequent genetic changes in receptor related to prostate cancer care could cause treatment resistance

Wednesday, November 30, 2016

Frequent genetic rearrangements in the androgen receptor could be limiting treatment options for prostate cancer patients, according to new research out of the University of Minnesota. Currently, the main treatment for prostate cancer inhibits androgen receptor activity. However, the new paper identified frequent rearrangements in the metastases of prostate cancer, allowing cancer cells to accumulate a variety of receptor forms and increasing resistance to treatments.

The paper is published in the latest issue of Nature Communications.

“We knew genetic rearrangements in the androgen receptor occurred in laboratory models of prostate cancer progression, and this could promote therapeutic resistance,” said Scott Dehm, Ph.D., associate professor in the Department of Laboratory Medicine and Pathology in the University of Minnesota Medical School and a member of the Masonic Cancer Center, University of Minnesota. “An outstanding question was if this reflected a mechanism of therapeutic resistance in prostate cancer patients, or whether it was unique to laboratory models.”